Role of cytogenetic studies in the treatment of chronic myeloid leukemia by tyrosine kinase inhibitors.

被引：0
|
作者：
Domracheva, E. V. [1 ]
Aseeva, E. A. [1 ]
机构：
[1] Minist Publ Hlth Russia, Hematol Res Ctr, Moscow, Russia
来源：
GEMATOLOGIYA I TRANSFUZIOLOGIYA | 2007年 / 52卷 / 02期
关键词：
chronic myeloid leukemia; gleevek; oncohematological cytogenetic laboratories in Russia;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Role of cytogenetic studies in the treatment of chronic myeloid leukemia by tyrosine kinase inhibitors. E.V.Domracheva, E.A.Aseeva. Hematology Research Center, Moscow. The significance of molecular cytogenetic studies for the diagnosis and monitoring of chronic myeloid leukemia during gleevek therapy is postulated. Problems in organization of cytogenetic service in Russia are formulated and approaches to solution of these problems are recommended. Prospective trends in studies of new drugs (tyrosine kinase inhibitors) by molecular cytogenetic methods are offered.
引用
收藏
页码：25 / 28
页数：4
相关论文
共 50 条
  • [1] Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
    Tolomeo, Manlio
    Dieli, Francesco
    Gebbia, Nicola
    Simoni, Daniele
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (08) : 853 - 863
  • [2] The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
    Pophali, Priyanka A.
    Patnaik, Mrinal M.
    CANCER JOURNAL, 2016, 22 (01): : 40 - 50
  • [3] New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
    Kimura, Shinya
    Ashihara, Eishi
    Maekawa, Taira
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2006, 7 (05) : 371 - 379
  • [4] CYTOGENETIC CHARACTERIZATION OF CHRONIC MYELOID LEUKEMIA AND ITS PROGNOSTIC IMPACT UPON TREATMENT WITH TYROSINE KINASE INHIBITORS
    Canamero, Giro Eloi
    Garcia, Olga
    Boque, Concepcion
    Sitges, Marta
    Vallansot, Rolando Omar
    Cisneros, Adela
    Cortes, Montserrat
    Gener, Georgina
    Vela, Dolors
    Font, Llorenc
    Pineda, Alberto
    Xandri, Marisol
    Santafe, Encarnacion
    Espasa, Andrea
    Comes, Martina
    Xicoy, Blanca
    Zamora, Lurdes
    Granada, Isabel
    Navarro, Jose Tomas
    Grau, Javier
    HAEMATOLOGICA, 2020, 105 : 169 - 170
  • [5] Tyrosine kinase inhibitors in chronic myeloid leukemia
    Sawyers, CL
    Druker, B
    CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 1999, 5 (02): : 63 - 69
  • [6] Musculoskeletal symptoms in chronic myeloid leukemia patients after stopping tyrosine kinase inhibitors.
    Diab, Maria
    Jeyakunnar, Ghayathri
    Schiffer, Charles Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] The role of new tyrosine kinase inhibitors in chronic myeloid leukemia in Kyrgyzstan
    Bayzakova, D.
    Zhusupova, S.
    LEUKEMIA RESEARCH, 2018, 73 : S44 - S45
  • [8] When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
    Pierre Laneuville
    Current Treatment Options in Oncology, 2018, 19
  • [9] When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
    Laneuville, Pierre
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (03)
  • [10] ASSESSMENT OF EFFICACY OF TYROSINE KINASE INHIBITORS IN TREATMENT OF CHRONIC MYELOID LEUKEMIA
    Yadrikhinskaya, V. N.
    Mulina, I. I.
    Sannikova, A. N.
    Palshina, A. M.
    Sleptsova, S. S.
    Aleksandrova, T. N.
    YAKUT MEDICAL JOURNAL, 2016, (04): : 30 - 33
12345